Heplisav-B®在HIV感染者既往乙肝疫苗无应答者中的血清学应答
本研究为回顾性横断面研究,纳入67例既往接种Engerix-B®或Recombivax-HB®后未产生保护性抗体的HIV感染者,评估接种至少两剂Heplisav-B®后的血清阳转率。结果显示86.6%的受试者在完成接种至少两个月后抗-HBs > 10 mIU/mL,表明Heplisav-B®在该人群中高效。
要点
- 既往无应答的HIV感染者接种Heplisav-B®后血清阳转率达86.6%。
- 未产生免疫的9例中,3例HIV RNA可检出,3例CD4计数<200 cells/uL。
- Heplisav-B®对传统重组乙肝疫苗无应答的HIV感染者高度有效。
核心结论
- Heplisav-B®在既往对非佐剂重组乙肝疫苗无应答的HIV感染者中能高效诱导HBV免疫。
研究设计与样本
- 回顾性横断面研究,于纽约布鲁克林医院中心HIV初级保健诊所开展。
- 纳入67例HIV阳性成人,既往接种Engerix-B®或Recombivax-HB®后未血清阳转,且至少接种两剂Heplisav-B®。
主要发现
- 9例(13.4%)未产生免疫者中,3例(33%)HIV RNA可检出,3例(33%)CD4计数<200 cells/uL。
关键数值与推荐
- 血清阳转定义为抗-HBs > 10 mIU/mL。
- 既往传统重组乙肝疫苗无应答者中,历史血清阳转率最高70%。
临床怎么用
- 对既往乙肝疫苗无应答的HIV感染者,可考虑使用Heplisav-B®进行再免疫。
- 接种后应检测抗-HBs以确认血清阳转。
局限性
- 回顾性、横断面设计,样本量较小(67例)。
- 未设对照组,无法直接比较Heplisav-B®与其他疫苗的应答率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As people living with HIV (PLWH) are at risk for contracting Hepatitis B Virus (HBV), they should be screened for HBV and vaccinated if not immune. Seroconversion rates in PLWH receiving traditional recombinant HBV vaccines (Engerix-B® and Recombivax-HB®) have historically been low with at most 70% achieving immunity. In 2017, a recombinant, adjuvanted HBV vaccine (Heplisav-B®) was approved for use in HIV-negative patients. Heplisav-B® has shown superior seroprotection in this population compared to Engerix-B® and Recombivax-HB®, as well as interim analysis showing higher seropositivity rates in patients undergoing dialysis. However, its efficacy in PLWH is currently unknown. This study evaluates the rate of seroconversion following Heplisav-B® administration in PLWH with previous HBV vaccination failure. METHODS: Retrospective, cross-sectional study at The Brooklyn Hospital Center's HIV primary care clinic in Brooklyn, NY. HIV-positive adults who received at least two doses of Heplisav-B® and had previously failed to seroconvert after vaccination with Engerix-B® or Recombivax-HB® were included. The primary outcome is the percentage of PLWH who became seropositive following Heplisav-B®. RESULTS: A total of 67 patients met the inclusion criteria. Twenty-five (37.3%) PLWH had failed at least 2 courses of recombinant vaccines. Fifty-eight (86.6%) PLWH became seropositive (Anti-HBs > 10 mIU/mL) at least two months after completing Heplisav-B®. For the 9 (13.4%) patients that did not develop immunity, 3 (33%) had a detectable HIV RNA and 3 (33%) had a CD4 count < 200 cells/uL3. CONCLUSIONS: Heplisav-B® was highly effective in achieving immunity to HBV in PLWH who failed non-adjuvanted recombinant vaccines.
引用
- Khaimova R, Fischetti B, Cope R, et al. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. Vaccine. 2021. PMID: 34600748. doi:10.1016/j.vaccine.2021.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。